Condition: HER2-positive Breast Cancer · Metastatic Cancer · Metastatic Breast Cancer · Sponsor: QuantumLeap Healthcare Collaborative
I-SPY Phase I/Ib (I-SPY-P1) is an open-label, multisite platform study designed to evaluate single agents or combinations in a metastatic treatment setting that may be relevant for breast cancer patients with the overall goal of moving promising drug regimens into the I-SPY 2 SMART Design Trial (NCT01042379) and/or other oncology-based trials in a timely manner.
This description comes directly from the study's public registry record.
Smita M Asare · (855) 866-0505 · smita.asare@quantumleaphealth.org
Maria Pitsiouni, PhD · (415) 651-8047 · m.pitsiouni@quantumleaphealth.org
Always discuss trial participation with your own doctor first.
| The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center | Birmingham, Alabama, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| The University of Chicago Medicine Comprehensive Cancer Center | Chicago, Illinois, United States | Recruiting |
| UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital | New Lenox, Illinois, United States | Recruiting |
| UChicago Medicine Orland Park | Orland Park, Illinois, United States | Recruiting |
| University of Minnesota Masonic Cancer Center | Minneapolis, Minnesota, United States | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05868226